SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

Search

Pharming Group NV

Fechado

0.852 2.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.819

Máximo

0.863

Indicadores-chave

By Trading Economics

Rendimento

4.3M

3.4M

Vendas

18M

93M

EPS

-0.02

Margem de lucro

3.657

Funcionários

404

EBITDA

1.9M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+141.09% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

119M

609M

Abertura anterior

-2.05

Fecho anterior

0.852

Pharming Group NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2025, 22:52 UTC

Ganhos
Grandes Movimentos do Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 de mai. de 2025, 20:37 UTC

Principais Notícias
Ganhos

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 de mai. de 2025, 00:00 UTC

Conversa de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 de mai. de 2025, 23:47 UTC

Conversa de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de mai. de 2025, 23:14 UTC

Principais Notícias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 de mai. de 2025, 22:46 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 21:58 UTC

Ganhos

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 de mai. de 2025, 21:24 UTC

Ganhos

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 de mai. de 2025, 20:56 UTC

Conversa de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 de mai. de 2025, 20:54 UTC

Conversa de Mercado
Ganhos

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 de mai. de 2025, 20:54 UTC

Ganhos

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 de mai. de 2025, 20:51 UTC

Ganhos

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de mai. de 2025, 20:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 de mai. de 2025, 20:50 UTC

Ganhos

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 de mai. de 2025, 20:26 UTC

Principais Notícias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 de mai. de 2025, 20:25 UTC

Ganhos

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparação entre Pares

Variação de preço

Pharming Group NV Previsão

Preço-alvo

By TipRanks

141.09% parte superior

Previsão para 12 meses

Média 2.001 EUR  141.09%

Máximo 2 EUR

Mínimo 2 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Pharming Group NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.